Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?

Marcus Fernando Kodama Pertille Ramos Marina Alessandra PereiraLarissa C AmorimEvandro S de MelloSheila F FarajUlysses RibeiroPaulo M G HoffIvan CecconelloTiago B de Castria

Published in: Journal of surgical oncology (2019)

CMT showed different impact on the survival of CG according to the molecular subtype. No survival benefit was observed for EBV and MSI groups who received CMT. GC with p53-aberrant had a significant benefit in survival with standard therapy.

Keyphrases

free survival
machine learning
epstein barr virus
stem cells
single molecule
mass spectrometry
bone marrow
cell therapy